About ELLIPSYS
Overview
Ellipsys (operating as Ellipsys Capital Corp) is a financial services firm established in 2019 and registered in Mauritius. It presents itself as a one-stop destination for trading a variety of financial instruments, including currencies, CFDs, commodities, indices, and futures. The broker provides access through widely recognised platforms such as MetaTrader 4 and VertexFX 11, with its own branded versions called ZEN Trader and ZEN Pro.
The broker's website claims a presence in Panama, listing a corporate office there, and provides a UK telephone number. However, its official registration is in Mauritius, and it is not regulated by any recognised financial authority. This regulatory gap is a critical factor for potential clients to consider.
Trading Platforms and Tools
Ellipsys promotes its ZEN Trader platform, which is essentially MetaTrader 4, a popular choice among retail forex traders. The platform is available for desktop and mobile devices, offering standard charting tools and execution features. Additionally, the broker mentions a 'Zen Pro' platform, though details are sparse on the website. The inclusion of VertexFX 11 in the known facts suggests an alternative proprietary platform, but the website primarily highlights MT4.
The broker emphasises 'real-time direct electronic access' and a 'customer-friendly online trading platform' that allows trading from anywhere at any time. No information about advanced tools or educational resources is evident on the site.
Market Instruments
According to its website, Ellipsys covers a broad range of asset classes: forex pairs, contracts for difference (CFDs) on indices and commodities, futures, and possibly other derivatives. The product guide distinguishes between exchange-traded and off-exchange contracts, indicating that some instruments may be traded over-the-counter.
Specific spreads or margin requirements are not published on the public pages, though a 'Spreads and Margin' page exists with placeholder content. The broker claims 'no hidden fees' for its value investing offering, but retail wholesale clients likely face standard markups.
Account Types and Funding Methods
The broker offers demo accounts for practice and live accounts for real trading. The only funding method explicitly mentioned on the site is bank wire transfer, with a note that local deposit/withdrawal options may be available through regional representatives. This suggests limited payment flexibility compared to brokers offering credit/debit cards or e-wallets.
Minimum deposit requirements are not disclosed, and account tiers (standard, premium, etc.) are not described. Clients are expected to maintain adequate margin, as risk disclosure statements indicate.
Regulatory and Licensing Status
Ellipsys is registered in Mauritius as a company, but it holds no licence from a recognised financial regulator. The known facts explicitly state 'NONE' under regulators. The broker's website does not display any regulatory credentials or membership in compensation schemes. This absence places the broker in a high-risk category, as traders have no recourse to an ombudsman or investor protection fund.
The contact details show a Panama office, which may indicate a second jurisdiction, but no evidence of oversight there either. For safety-conscious traders, this lack of regulation is a major red flag.
Target Clientele
Ellipsys appears to target international retail traders, particularly those seeking exposure to a wide range of markets from a single account. The broker's use of familiar platforms like MT4 may appeal to experienced traders, while the availability of demo accounts could attract beginners.
However, given its unregulated status, the broker is likely not suitable for risk-averse traders or those in jurisdictions where dealing with unlicensed entities is prohibited. The client base is probably composed of traders willing to accept higher risk for potentially higher leverage and access to niche instruments.
Overview compiled by FXCanary from regulatory records and public data. full ELLIPSYS review